Clinicians now would be able to use uridine monophosphate (high doses) in combination with choline (the supplement neurouridine) to treat patients with non-specific low back pain.

An open observational (MULTINEURO-1) trial was conducted on the safety and efficacy of elevated doses (150 mg) of uridine monophosphate  in combination with choline to treat individuals having low back pain.

The study recruited 50 patients suffering from non-specific low back pain. For evaluating the efficacy, the following scales were utilized: (a) the painDETECT questionnaire (PD-Q), (b) the Hospital Anxiety and Depression Scale (HADS), (c) Visual Analogue scale (VAS), (d) the Roland-Morris Low Back Pain and Disability Questionnaire (RMQ), and (e) the Pittsburgh Sleep Quality Index

A greater decline in the pain intensity was noted in the main group than in the comparison group. The results of PD-Q illustrated a remarkable decline in the severity of the neuropathic component of pain in the treatment group. The RMQ revealed signs of improved functional status.

High doses of uridine monophosphate in combination with supplement neurouridine appear to yield satisfactory outcomes in patients with nonspecific acute low back pain.